The submission of additional information, upon the request of the US regulator, has delayed the action date for Bristol-Myers Squibb’s (NYSE: BMY) CAR-T cell candidate lisocabtagene maraleucel (liso-cel).
The firm has submitted an application to market the CD19-directed therapy for adults with relapsed or refractory large B-cell lymphoma, in the third-line setting.
The new Prescription Drug User Fee Act (PDUFA) action date is November 16, 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze